Literature DB >> 8411393

Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element.

G Li1, J Lisziewicz, D Sun, G Zon, S Daefler, F Wong-Staal, R C Gallo, M E Klotman.   

Abstract

The interaction between the Rev protein of human immunodeficiency virus type 1 and its highly structured and conserved RNA target, the Rev-responsive element, is required for virus replication. We demonstrate that antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element effectively inhibit Rev activity, as well as human immunodeficiency virus type 1 replication, and are candidates for antiviral therapy.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8411393      PMCID： PMC238137     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  69 in total

1.  Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein.

Authors:  L S Tiley; M H Malim; H K Tewary; P G Stockley; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

2.  Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein.

Authors:  E T Dayton; D A Konings; D M Powell; B A Shapiro; L Butini; J V Maizel; A I Dayton
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  A second post-transcriptional trans-activator gene required for HTLV-III replication.

Authors:  J Sodroski; W C Goh; C Rosen; A Dayton; E Terwilliger; W Haseltine
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

4.  The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs.

Authors:  D M D'Agostino; B K Felber; J E Harrison; G N Pavlakis
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

5.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

6.  Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome.

Authors:  B Safai; M G Sarngadharan; J E Groopman; K Arnett; M Popovic; A Sliski; J Schüpbach; R C Gallo
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

Review 7.  Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions.

Authors:  G Zon; T G Geiser
Journal:  Anticancer Drug Des       Date:  1991-12

8.  Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.

Authors:  J Lisziewicz; D Sun; M Klotman; S Agrawal; P Zamecnik; R Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728
View more
  7 in total

1.  Identification and characterization of a cell membrane nucleic acid channel.

Authors:  B Hanss; E Leal-Pinto; L A Bruggeman; T D Copeland; P E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

2.  Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition.

Authors:  Y Wu; L Duan; M Zhu; B Hu; S Kubota; O Bagasra; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 3.  Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.

Authors:  G Zon
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

4.  Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein.

Authors:  T Nakaya; S Iwai; K Fujinaga; Y Sato; E Otsuka; K Ikuta
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

5.  Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy.

Authors:  R A Furuta; S Kubota; M Maki; Y Miyazaki; T Hattori; M Hatanaka
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  Chimeric RNase H-competent oligonucleotides directed to the HIV-1 Rev response element.

Authors:  Chrissy E Prater; Anthony D Saleh; Maggie P Wear; Paul S Miller
Journal:  Bioorg Med Chem       Date:  2007-06-02       Impact factor: 3.641

7.  Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses.

Authors:  D Archambault; C A Stein; J S Cohen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.